Bacteriotherapy for clostridium difficile colitis
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
1. A bacteriotherapy composition in oral dosage form, comprising:
a bacteriotherapy composition contained within an oral capsule, prepared by a process comprising:
collecting a first fecal sample from a donor,
processing the first fecal sample to form a first processed fecal sample, wherein processing the first fecal sample comprises homogenizing, filtering, and adding a cryoprotectant to the first fecal sample to obtain a first processed fecal sample,
storing the first processed fecal sample in a cold storage device,
collecting a second fecal sample from the donor,
processing the second fecal sample to form a second processed fecal sample, wherein processing the second fecal sample comprises homogenizing, filtering, and adding a cryoprotectant to the second fecal sample to obtain a second processed fecal sample,
storing the second processed fecal sample in a cold storage device,
combining the first processed fecal sample with the second processed fecal sample to obtain the bacteriotherapy composition, and
encapsulating the bacteriotherapy composition within an oral capsule.
2. The bacteriotherapy composition of claim 1 , wherein the cryoprotectant added to the first fecal sample comprises a glycol.
3. The bacteriotherapy composition of claim 1 , wherein processing the first fecal sample to form a first processed fecal sample occurs within a day of collecting the first fecal sample from the donor.
4. The bacteriotherapy composition of claim 1 , wherein the capsule comprises an enteric coating.
5. A method for manufacturing a bacteriotherapy composition in oral dosage form, the method comprising:
collecting a first fecal sample from a donor;
processing the first fecal sample to form a first processed fecal sample, wherein processing the first fecal sample comprises homogenizing, filtering, and adding a cryoprotectant to the first fecal sample to obtain a first processed fecal sample;
storing the first processed fecal sample in a cold storage device;
collecting a second fecal sample from the donor;
processing the second fecal sample to form a second processed fecal sample, wherein processing the second fecal sample comprises homogenizing, filtering, and adding a cryoprotectant to the first fecal sample to obtain a first processed fecal sample;
storing the second processed fecal sample in a cold storage device;
combining the first processed fecal sample with the second processed fecal sample to form the bacteriotherapy composition;
and
encapsulating the bacteriotherapy composition within an oral capsule.
6. The method of claim 5 , wherein the cryoprotectant added to the first fecal sample comprises a glycol.
7. The method of claim 5 , wherein processing the first fecal sample to form a first processed fecal sample occurs within a day of collecting the first fecal sample from the donor.
8. The method of claim 5 , further comprising disposing an enteric coating on the capsule.
9. The method of claim 5 , wherein storing the first processed fecal sample in a cold storage device includes storing the first processed fecal sample with dry ice.
10. The method of claim 5 , wherein storing the first processed fecal sample in a cold storage device includes storing the first processed fecal sample at a temperature of about −20 degrees Celsius or colder.
11. An oral bacteriotherapy composition, comprising:
an oral capsule containing a plurality of processed fecal samples from a single donor that have been individually cooled and then pooled, wherein at least one of the plurality of processed fecal samples comprises a cryoprotectant.
12. The oral bacteriotherapy composition of claim 11 , wherein an enteric coating is disposed on the oral capsule.
13. The oral bacteriotherapy composition of claim 11 , wherein the cryoprotectant comprises a glycol.
14. The bacteriotherapy composition of claim 2 , wherein the cryoprotectant added to the second fecal sample comprises a glycol.
15. The method of claim 6 , wherein the cryoprotectant added to the second fecal sample comprises a glycol.
16. The bacteriotherapy composition of claim 1 , wherein storing the first processed fecal sample in a cold storage device includes storing the first processed fecal sample at a temperature of about −20 degrees Celsius or colder.
17. The bacteriotherapy composition of claim 1 , wherein storing the second processed fecal sample in a cold storage device includes storing the second processed fecal sample at a temperature of about −20 degrees Celsius or colder.
18. The method of claim 5 , wherein storing the second processed fecal sample in a cold storage device includes storing the second processed fecal sample at a temperature of about −20 degrees Celsius or colder.